Profile data is unavailable for this security.
About the company
GH Research PLC is a clinical-stage biopharmaceutical company. The Company is engaged in offering treatment for psychiatric and neurological disorders. The Company's pipeline includes GH001, GH002 and GH003. The Company focuses on developing its 5- Methoxy-N, N-Dimethyltryptamine, (5-MeO-DMT), therapies for the treatment of patients with Treatment Resistant Depression (TRD). Its product candidate, GH001, is formulated for 5-MeO-DMT administration via an inhalation approach. With GH001, the Company has completed two Phase 1 healthy volunteer clinical trials and a Phase 1/2 clinical trial in patients with treatment-resistant depression (TRD). The GH002 is a 5-MeO-DMT product candidate formulated for administration via an injectable approach. GH002 has completed pre-clinical development to support early clinical trials. The GH003 is a 5-MeO-DMT product candidate formulated for administration via an intranasal administration approach.
- Revenue in USD (TTM)0.00
- Net income in USD-35.59m
- Incorporated2021
- Employees49.00
- LocationGH Research PLCJoshua Dawson House, Dawson StreetDublin D02 RY95IrelandIRL
- Phone+353 14378334
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lyell Immunopharma Inc | 130.00k | -234.63m | 553.21m | 224.00 | -- | 0.8414 | -- | 4,255.48 | -0.9353 | -0.9353 | 0.0005 | 2.58 | 0.0002 | -- | -- | 580.36 | -27.81 | -- | -29.04 | -- | -- | -- | -180,486.20 | -- | -- | -- | 0.00 | -- | -99.85 | -- | -28.13 | -- | -- | -- |
| Arrivent Biopharma Inc | 0.00 | -69.33m | 553.32m | 40.00 | -- | -- | -- | -- | -2.17 | -2.17 | 0.00 | 4.73 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -87.86 | -- | -- | -- |
| Northwest Biotherapeutics Inc | 1.93m | -64.37m | 553.34m | 25.00 | -- | -- | -- | 286.41 | -0.0573 | -0.0573 | 0.0017 | -0.04 | 0.0653 | -- | -- | 77,280.00 | -211.53 | -381.58 | -- | -- | -- | -- | -3,240.11 | -6,479.25 | -- | -- | -- | -- | 14.80 | 36.21 | 38.71 | -- | 77.88 | -- |
| IGM Biosciences Inc | 2.13m | -246.42m | 567.72m | 224.00 | -- | 2.78 | -- | 266.53 | -4.81 | -4.81 | 0.0407 | 3.46 | 0.0046 | -- | -- | 9,508.93 | -52.60 | -44.66 | -58.00 | -48.20 | -- | -- | -11,568.83 | -23,668.96 | -- | -- | 0.00 | -- | 99.25 | -- | -11.45 | -- | 73.48 | -- |
| Olema Pharmaceuticals Inc | 0.00 | -96.66m | 568.65m | 74.00 | -- | 2.20 | -- | -- | -2.16 | -2.16 | 0.00 | 4.62 | 0.00 | -- | -- | 0.00 | -39.24 | -30.06 | -42.54 | -31.40 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.76 | -- | -- | -- |
| GH Research PLC | 0.00 | -35.59m | 570.23m | 49.00 | -- | 2.60 | -- | -- | -0.6841 | -0.6841 | 0.00 | 4.21 | 0.00 | -- | -- | 0.00 | -14.81 | -- | -15.16 | -- | -- | -- | -- | -- | -- | -- | 0.0044 | -- | -- | -- | -58.47 | -- | -- | -- |
| Stoke Therapeutics Inc | 8.78m | -104.70m | 574.86m | 110.00 | -- | 3.17 | -- | 65.47 | -2.38 | -2.38 | 0.1996 | 3.47 | 0.0363 | -- | 26.94 | 79,827.27 | -43.23 | -31.62 | -49.60 | -33.92 | -- | -- | -1,192.34 | -1,775.50 | -- | -- | 0.00 | -- | -29.22 | -- | -3.59 | -- | 11.56 | -- |
| Aerovate Therapeutics Inc | 0.00 | -75.52m | 575.04m | 51.00 | -- | 5.08 | -- | -- | -2.87 | -2.87 | 0.00 | 3.94 | 0.00 | -- | -- | 0.00 | -57.49 | -- | -63.65 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -46.61 | -- | -- | -- |
| Castle Biosciences Inc | 219.79m | -57.47m | 581.81m | 610.00 | -- | 1.48 | -- | 2.65 | -2.15 | -2.15 | 8.20 | 14.27 | 0.488 | 7.55 | 7.12 | 360,308.20 | -12.76 | -9.43 | -14.07 | -10.17 | 79.53 | 80.58 | -26.15 | -28.46 | 6.04 | -- | 0.0003 | -- | 60.38 | 57.35 | 14.41 | -- | 117.94 | -- |
| Compass Pathways PLC (ADR) | 0.00 | -118.46m | 585.70m | 186.00 | -- | 2.35 | -- | -- | -2.39 | -2.39 | 0.00 | 3.64 | 0.00 | -- | -- | 0.00 | -50.06 | -40.85 | -54.08 | -44.48 | -- | -- | -- | -- | -- | -- | 0.113 | -- | -- | -- | -29.46 | -- | -12.68 | -- |
| Prime Medicine Inc | 0.00 | -198.13m | 590.10m | 234.00 | -- | 3.60 | -- | -- | -2.17 | -2.17 | 0.00 | 1.37 | 0.00 | -- | -- | 0.00 | -71.51 | -- | -84.13 | -- | -- | -- | -- | -- | -- | -85.97 | 0.00 | -- | -- | -- | -39.52 | -- | -- | -- |
| ORIC Pharmaceuticals Inc | 0.00 | -100.70m | 595.34m | 100.00 | -- | 2.16 | -- | -- | -1.97 | -1.97 | 0.00 | 4.08 | 0.00 | -- | -- | 0.00 | -40.34 | -33.92 | -43.47 | -35.77 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -12.99 | -- | 10.09 | -- |
| Wave Life Sciences Ltd | 113.31m | -57.51m | 602.86m | 266.00 | -- | 14.82 | -- | 5.32 | -0.5397 | -0.5397 | 1.07 | 0.3987 | 0.5378 | -- | -- | 425,958.70 | -27.30 | -56.98 | -70.41 | -102.38 | -- | -- | -50.76 | -353.20 | -- | -- | 0.00 | -- | 3,005.10 | 51.04 | 64.46 | -- | -35.44 | -- |
Data as of May 01 2024. Currency figures normalised to GH Research PLC's reporting currency: US Dollar USD
54.36%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BVF Partners LPas of 31 Dec 2023 | 10.40m | 19.99% |
| RA Capital Management LPas of 31 Dec 2023 | 5.59m | 10.74% |
| RTW Investments LPas of 31 Dec 2023 | 3.33m | 6.40% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 3.14m | 6.03% |
| Lynx1 Capital Management LPas of 06 Feb 2024 | 2.99m | 5.76% |
| Verition Fund Management LLCas of 31 Dec 2023 | 1.16m | 2.23% |
| Cormorant Asset Management LPas of 31 Dec 2023 | 593.04k | 1.14% |
| Deep Track Capital LPas of 31 Dec 2023 | 499.40k | 0.96% |
| Checkpoint Capital LPas of 31 Dec 2023 | 293.95k | 0.57% |
| Morgan Stanley Investment Management, Inc.as of 31 Dec 2023 | 288.09k | 0.55% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
